The newest drugs for the treatment of hepatitis C include Mavyret (glecaprevir and pibrentasvir), Vosevi (sofosbuvir, velpatasvir, and voxilaprevir), and Epclusa (sofosbuvir and velpatasvir).

Mavyret, Vosevi, and Epclusa are all FDA-approved for the treatment of chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).

• Mavyret is used to treat patients 3 years of age and older. Mavyret is also approved for patients 3 years and older with HCV genotype 1 infection, who have previously been treated with an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.
• Vosevi is indicated for use in the treatment of adult patients. It is used as a re-treatment option in patients who have been previously treated with an NS5A inhibitor-containing regimen (GT1-6), or a regimen containing sofosbuvir without an NS5A inhibitor (GT1a or GT3).
• Epclusa is approved for use in adults and children 3 years of age and older. Epclusa is also approved in adults and children 3 years of age and older for the treatment of HCV genotype 1, 2, 3, 4, 5 or 6 in patients with decompensated cirrhosis (for use in combination with ribavirin).

Latest FDA Approvals for Hepatitis C